Genentech, Inc.

Astrazeneca Ab

F. Hoffmann-la Roche Ag

Yun-Xing Cheng

Lei Zhang

Mark Edward Zak

Wei Li

F Anthony Romero

Simon Charles Goodacre

Paul Gibbons

Terry Kellar

Nicholas Charles Ray

Miroslaw Jerzy Tomaszewski

Po-wai Yuen

Guiling Zhao

Rohan V Mendonca

Naomi S Rajapaksa

Marian C Bryan

Jessica Grandner

Daniel G M Shore

Snahel Patel

Christopher Walpole

Sharada Shenvi Labadie

James John Crawford

Richard Pastor

Po-Wai Yuen

Emily J Hanan

Gregory Hamilton

Guosheng Wu

Marie-Gabrielle Braun

Hua Yang

Matthew W Cartwright

Xuehong Luo

Keira Garland

Anthony F Romero

Vijayaratnam Santhakumar

Christine Edwards

Yuhong Fu

Mehrnaz Pourashraf

Po-Wei Yuen

Mohammed Sajad

Rongbao Hua

Limin Cheng

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Cyclic peptide antibiotics

Compounds of formula (I) wherein R, R, R, R, Rand Rare as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases

Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Therapeutic compounds, compositions and methods of use thereof

Compounds of formula (I) wherein R, R, R, R, Rand Rare as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Pyrazolopyrimidine inhibitors of JAK kinases and uses thereof

Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.

Pyrazolopyrimidine compounds and methods of use thereof

Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Therapeutic compounds and compositions, and methods of use thereof

Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

Triazolopyridine compounds, compositions and methods of use thereof

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof

Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R, R, X, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Piperidine derivatives and their use as muscarinic receptor modulators

Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein A, A, G, GG, R, R, X, Y, Z, m, n and p are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Compounds

Compounds of general formula (I), are disclosed and claimed in the present application, as well as salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain

Growing community of inventors

Beijing, China

Yun-Xing Cheng